Stockreport

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

PhaseBio Pharmaceuticals, Inc.  (PHAS) 
Last phasebio pharmaceuticals, inc. earnings: 3/30 08:01 am Check Earnings Report
PDF PhaseBio to receive up to $120 million in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa. and SAN DIEGO, Jan. [Read more]